Entity trail

Eli Lilly

Source-backed findings, relationship evidence, citations, and briefing history from the public MindPattern archive.

Briefing refs

Findings

Edges

Sources

Corpus findings

2026-08-13 / rss-researcherChai Discovery closed four pharma deals this summer — Lilly, Novartis and argenx — on a $400M Series C at $4BLatent Space interviews Chai Discovery cofounder Matt McPartlon and product lead Neil Patil on what changed in bio-AI commercially: three new major pharma deals (Lilly, Novartis, argenx) plus an expansion of the existing Eli Lilly program since June, against a $400M OpenAI-backed Series C at a $4 billion valuation. The technical pitch is binding-affinity modeling and bi-specific antibody design aimed at 'one-shotting molecules' to cut lab iteration, and the product thesis is deliberately anti-chatbot — their molecule editor is built like a CAD or graphics program. McPartlon's line for the pattern: 'protein tokens have the highest downstream value of any token.'
2026-07-15 / news-researcherChai Discovery Raises $400M Series C, Tripling Valuation to $3.8B in Seven MonthsAI molecular-design startup Chai Discovery closed a $400M Series C led by Index Ventures (with Kleiner Perkins, Sequoia, Dimension, and existing backers Thrive, OpenAI, Menlo, General Catalyst), lifting its valuation to $3.8B from $1.3B in December — total funding now ~$630M. Its new Chai-3 model roughly doubles molecular-interaction hit rates (to ~35–40%) and is already deployed at commercial scale inside Eli Lilly, Novartis, and Pfizer. A concrete data point that AI-designed antibodies are reaching Big Pharma production, not just research.
2026-05-10 / sources-researcherEli Lilly Inaugurates LillyPod — Pharma's Most Powerful AI Supercomputer with 1,016 Blackwell GPUsEli Lilly inaugurated LillyPod, the pharmaceutical industry's most powerful AI supercomputer, built on an NVIDIA DGX SuperPOD with 1,016 Blackwell Ultra GPUs delivering over 9,000 petaflops. Positioned for drug discovery acceleration and molecular simulation at unprecedented scale.
2026-04-18 / hn-researcherNovo Nordisk Partners with OpenAI to Integrate AI Across Drug Discovery, Manufacturing, and OperationsNovo Nordisk announced a strategic partnership with OpenAI on April 14 to deploy AI across its entire pipeline — from drug discovery and clinical trials to manufacturing, supply chains, and commercial operations. Pilot programs launch immediately with full integration planned by end of 2026. The Danish pharma giant is locked in a race with Eli Lilly for weight-loss market dominance and is using the partnership to accelerate next-generation drugs beyond its Wegovy franchise. OpenAI will also assist in upskilling Novo's global workforce. Covered by CNBC, Bloomberg, and Euronews.

Graph relationships

PARTNERS WITH
Chai Discovery
Chai Discovery closed pharma deal with Eli Lilly.
Source finding
USES
Chai-3
Eli Lilly deployed Chai-3 at commercial scale for molecular design.
Source finding
USES
DGX SuperPOD
Eli Lilly's LillyPod supercomputer uses NVIDIA DGX SuperPOD architecture.
Source finding
COMPETES WITH
Novo Nordisk
Novo Nordisk competes with Eli Lilly for weight-loss market dominance
Source finding
PARTNERS WITH
Chai Discovery -> Eli Lilly
Chai Discovery closed pharma deal with Eli Lilly.
Source finding
COMPETES WITH
Novo Nordisk -> Eli Lilly
Novo Nordisk competes with Eli Lilly for weight-loss market dominance
Source finding

Source trail

Latent Space SiliconANGLE Crescendo AI CNBC

Graph sources

entity graphfindings textkg edgeskg entities

Fetching from the wire…